NCT05961969

Brief Summary

The present study is to develop the novel robotic surgical technique and enhance the surgery quality for the treatment of distal rectal cancer.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 21, 2022

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

July 9, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

July 27, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

September 20, 2024

Status Verified

September 1, 2024

Enrollment Period

3.4 years

First QC Date

July 9, 2023

Last Update Submit

September 18, 2024

Conditions

Keywords

Intersphincteric resection (ISR)Transabdominal ISRTop-down ISRTransanal ISRRectal cancer

Outcome Measures

Primary Outcomes (1)

  • Completion of transabdominal ISR

    1. The total mobilization and transection of anorectum was performed in the transabdominal down sequence, followed by the double-stapling technique for the coloanal anastomosis; 2. the proximal and distal stapled tissue doughnuts recovered from EEA device were intact; 3. A variable length of muscular cuff of proximal internal anal sphincter was removed with a TME specimen; 4. To define a successful transabdominal total ISR, besides the above-mentioned three criteria, the anastomotic site should be checked by immediate anoscopy to confirm the stapling line is approximately at the level of anal intersphincteric groove.

    About one week

Secondary Outcomes (12)

  • Circumferential resection margin (CRM)

    About one week

  • Distal and proximal resection margin

    About one week

  • Length of operation time

    Through the completion of surgery, an average of 5 hours

  • Length of postoperative ileus

    30 days

  • Hospitalization

    After patients' discharge from hospital, an average of 7 days

  • +7 more secondary outcomes

Study Arms (1)

Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection

Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis

Procedure: Robotic surgery

Interventions

1. Patients with rectal cancer. 2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis

Patients undergoing robotic Transabdominal Top-down Intersphincteric Resection

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients diagnosed as rectal cancer and met with the above inclusion and exclusion criteria will be recruited.

You may qualify if:

  • cT1-3 or yT 1-3 rectal adenocarcinoma whose low border was located below the anorectal sling (4 cm from anal verge), in which the required surgery meets the definition of ISR;
  • Clinically Tumor-Node-Metastasis (TNM) stage I-III rectal adenocarcinoma;
  • Curative and elective surgery;
  • American Society of Anesthesiology (ASA) class Ⅰ to Ⅲ patients;
  • Age between 20 and 75 years.

You may not qualify if:

  • cT4 adenocarcinoma, i.e., the rectal cancer invaded to external sphincter or adjacent pelvic organs;
  • Evidence of distant metastasis;
  • Primary tumor mass≧8 cm in diameter;
  • Morbidly obese patients, i.e., body mass index (BMI) ≧ 40 kg/m2 ;
  • Previous major surgery of low upper abdomen;
  • The adenocarcinoma has invaded to lateral pelvic side wall requiring a lateral pelvic lymph node dissection. (7) Patients with poor anorectal function (Wexner incontinence Score≧ 10)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jin-Tung LIANG

Taipei, 886, Taiwan

RECRUITING

MeSH Terms

Conditions

Colorectal NeoplasmsRectal Neoplasms

Interventions

Robotic Surgical Procedures

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Surgery, Computer-AssistedSurgical Procedures, OperativeRoboticsAutomationTechnologyTechnology, Industry, and Agriculture

Study Officials

  • Jin-Tung LIANG, PhD

    National Taiwan University Hospital

    STUDY DIRECTOR

Central Study Contacts

Jin-Tung LIANG, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2023

First Posted

July 27, 2023

Study Start

February 21, 2022

Primary Completion

August 1, 2025

Study Completion

August 1, 2025

Last Updated

September 20, 2024

Record last verified: 2024-09

Locations